<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="aac"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC2764168/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers </title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC2764168_files/jig.min.css"><script type="text/javascript" src="./PMC2764168_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Antimicrobial Agents and Chemotherapy"><meta name="citation_title" content="Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers "><meta name="citation_authors" content="P. A. Pham, C. J. L. la Porte, L. S. Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner, D. W. Cameron"><meta name="citation_date" content="October 2009"><meta name="citation_issue" content="10"><meta name="citation_volume" content="53"><meta name="citation_firstpage" content="4385"><meta name="citation_doi" content="10.1128/AAC.00449-09"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2764168/?report=abstract"><meta name="citation_pmid" content="19667285"><meta name="DC.Title" content="Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers "><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="American Society for Microbiology (ASM)"><meta name="DC.Contributor" content="P. A. Pham"><meta name="DC.Contributor" content="C. J. L. la Porte"><meta name="DC.Contributor" content="L. S. Lee"><meta name="DC.Contributor" content="R. van Heeswijk"><meta name="DC.Contributor" content="J. P. Sabo"><meta name="DC.Contributor" content="M. M. Elgadi"><meta name="DC.Contributor" content="P. J. Piliero"><meta name="DC.Contributor" content="P. Barditch-Crovo"><meta name="DC.Contributor" content="E. Fuchs"><meta name="DC.Contributor" content="C. Flexner"><meta name="DC.Contributor" content="D. W. Cameron"><meta name="DC.Date" content="2009 Oct"><meta name="DC.Identifier" content="10.1128/AAC.00449-09"><meta name="DC.Language" content="en"><meta property="og:title" content="Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers "><meta property="og:type" content="article"><meta property="og:description" content="To identify pharmacokinetic (PK) drug-drug interactions between tipranavir-ritonavir (TPV/r) and rosuvastatin and atorvastatin, we conducted two prospective, open-label, single-arm, two-period studies. The geometric mean (GM) ratio was 1.37 (90% ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC2764168_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC2764168_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC2764168_files/common.min.js">//</script><script type="text/javascript" src="./PMC2764168_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC2764168_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC2764168_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC2764168_files/MathJax.js"></script><script type="text/javascript" src="./PMC2764168_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-aac.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/pdf/0449-09.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="8A1A2DA176C2A89100000000002C3B5D"><link type="text/css" rel="stylesheet" href="./PMC2764168_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC2764168_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC2764168%2F&ncbi_pdid=article&ncbi_phid=8A1A2DA176C2A89100000000002C3B5D'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC2764168_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a><ul id="resources-submenu" class="ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/all/" tabindex="-1" role="menuitem">All Resources</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#chemicals-bioassays" tabindex="-1" role="menuitem" class="expandRight">Chemicals &amp; Bioassays</a><ul class="actual-resources-submenu chemicals-bioassays ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pcassay" title=" Contributed bioactivity data for PubChem Substances " tabindex="-1" role="menuitem">PubChem BioAssay</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pccompound" title=" Unique, standardized chemical structures " tabindex="-1" role="menuitem">PubChem Compound</a></li><li role="presentation"><a href="https://pubchem.ncbi.nlm.nih.gov/search/search.cgi" title=" Searches PubChem Compound by chemical structure " tabindex="-1" role="menuitem">PubChem Structure Search</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pcsubstance" title=" Provides information on the biological activities of small molecules. " tabindex="-1" role="menuitem">PubChem Substance</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/chemicals-bioassays/" tabindex="-1" role="menuitem">All Chemicals &amp; Bioassays Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#dna-rna" tabindex="-1" role="menuitem" class="expandRight">DNA &amp; RNA</a><ul class="actual-resources-submenu dna-rna ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/" title=" DNA and RNA sequences submitted to NCBI " tabindex="-1" role="menuitem">GenBank</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank" title=" Web tool for simple submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: BankIt</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/Sequin/" title=" Software tool for complex submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: Sequin</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nuccore" title=" Nucleotide sequence data in GenBank and RefSeq " tabindex="-1" role="menuitem">Nucleotide Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/popset" title=" Sets of nucleotide sequences representing a population " tabindex="-1" role="menuitem">PopSet</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/" title=" Curated nucleotide and protein sequences produced by NCBI " tabindex="-1" role="menuitem">Reference Sequence (RefSeq)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?" title=" Database of sequences reads from next generation sequencing technologies " tabindex="-1" role="menuitem">Sequence Read Archive (SRA)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/trace.cgi" title=" DNA chromatograms, base calls, and quality estimates for single-pass reads. " tabindex="-1" role="menuitem">Trace Archive</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/unigene" title=" Gene-centered clusters of transcripts and ESTs " tabindex="-1" role="menuitem">UniGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/dna-rna/" tabindex="-1" role="menuitem">All DNA &amp; RNA Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#data-software" tabindex="-1" role="menuitem" class="expandRight">Data &amp; Software</a><ul class="actual-resources-submenu data-software ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml" title=" Program for viewing 3D structures and alignments " tabindex="-1" role="menuitem">Cn3D</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank" title=" Web tool for simple submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: BankIt</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/Sequin/" title=" Software tool for complex submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: Sequin</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="https://pubchem.ncbi.nlm.nih.gov/search/search.cgi" title=" Searches PubChem Compound by chemical structure " tabindex="-1" role="menuitem">PubChem Structure Search</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/SNP/" title=" The SNP database tools page provides links to the general submission guidelines and to the submission handle request. " tabindex="-1" role="menuitem">SNP Submission Tool</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/VAST/vast.html" title=" Tool that generates 3D structural alignments " tabindex="-1" role="menuitem">Vector Alignment Search Tool (VAST)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/data-software/" tabindex="-1" role="menuitem">All Data &amp; Software Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#domains-structures" tabindex="-1" role="menuitem" class="expandRight">Domains &amp; Structures</a><ul class="actual-resources-submenu domains-structures ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml" title=" Program for viewing 3D structures and alignments " tabindex="-1" role="menuitem">Cn3D</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/structure/" title=" Database of 3D macromolecular structures derived from PDB " tabindex="-1" role="menuitem">Structure (Molecular Modeling Database)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/VAST/vast.html" title=" Tool that generates 3D structural alignments " tabindex="-1" role="menuitem">Vector Alignment Search Tool (VAST)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/domains-structures/" tabindex="-1" role="menuitem">All Domains &amp; Structures Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#genes-expression" tabindex="-1" role="menuitem" class="expandRight">Genes &amp; Expression</a><ul class="actual-resources-submenu genes-expression ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gene" title=" Database of gene loci and associated transcripts and proteins " tabindex="-1" role="menuitem">Gene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/geo/" title=" Gene Expression Omnibus (GEO) Database " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Database </a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gds" title=" Curated collections of gene expression data sets " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Datasets</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/geoprofiles/" title=" Database of gene expression Profiles for individual sequences " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Profiles</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/homologene" title=" Sets of homologous eukaryotic genes " tabindex="-1" role="menuitem">HomoloGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/omim" title=" Database of human genes and genetic disorders " tabindex="-1" role="menuitem">Online Mendelian Inheritance in Man (OMIM)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/unigene" title=" Gene-centered clusters of transcripts and ESTs " tabindex="-1" role="menuitem">UniGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genes-expression/" tabindex="-1" role="menuitem">All Genes &amp; Expression Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#genetics-medicine" tabindex="-1" role="menuitem" class="expandRight">Genetics &amp; Medicine</a><ul class="actual-resources-submenu genetics-medicine ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books" title=" Online biomedical books " tabindex="-1" role="menuitem">Bookshelf</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gtr/" title=" Detailed information about genetic tests and labs " tabindex="-1" role="menuitem">Genetic Testing Registry</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/omim" title=" Database of human genes and genetic disorders " tabindex="-1" role="menuitem">Online Mendelian Inheritance in Man (OMIM)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed" title=" Biomedical literature abstracts " tabindex="-1" role="menuitem">PubMed</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/" title=" Free, full-text articles " tabindex="-1" role="menuitem">PubMed Central (PMC)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed/clinical" title=" Directory of PubMed queries about clinical topics " tabindex="-1" role="menuitem">PubMed Clinical Queries</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genetics-medicine/" tabindex="-1" role="menuitem">All Genetics &amp; Medicine Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#genomes-maps" tabindex="-1" role="menuitem" class="expandRight">Genomes &amp; Maps</a><ul class="actual-resources-submenu genomes-maps ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/dbvar" title=" A database of genomic structural variation " tabindex="-1" role="menuitem">Database of Genomic Structural Variation (dbVar)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sites/genome" title=" Curated genomic DNA sequences " tabindex="-1" role="menuitem">Genome</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/bioproject/" title=" Central status pages for genome sequencing projects " tabindex="-1" role="menuitem">Genome Project</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nuccore" title=" Nucleotide sequence data in GenBank and RefSeq " tabindex="-1" role="menuitem">Nucleotide Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/popset" title=" Sets of nucleotide sequences representing a population " tabindex="-1" role="menuitem">PopSet</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?" title=" Database of sequences reads from next generation sequencing technologies " tabindex="-1" role="menuitem">Sequence Read Archive (SRA)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/trace.cgi" title=" DNA chromatograms, base calls, and quality estimates for single-pass reads. " tabindex="-1" role="menuitem">Trace Archive</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genomes-maps/" tabindex="-1" role="menuitem">All Genomes &amp; Maps Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#homology" tabindex="-1" role="menuitem" class="expandRight">Homology</a><ul class="actual-resources-submenu homology ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/homologene" title=" Sets of homologous eukaryotic genes " tabindex="-1" role="menuitem">HomoloGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/proteinclusters" title=" Clusters of related proteins from prokaryotes and organelles " tabindex="-1" role="menuitem">Protein Clusters</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/homology/" tabindex="-1" role="menuitem">All Homology Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#literature" tabindex="-1" role="menuitem" class="expandRight">Literature</a><ul class="actual-resources-submenu literature ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books" title=" Online biomedical books " tabindex="-1" role="menuitem">Bookshelf</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nlmcatalog/journals" title=" Information on journals cited by NCBI records " tabindex="-1" role="menuitem">Journals in NCBI Databases</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mesh" title=" Controlled vocabulary for MEDLINE " tabindex="-1" role="menuitem">MeSH Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK143764/" title=" Introductory articles about NCBI resources " tabindex="-1" role="menuitem">NCBI Handbook</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK3831/" title=" Online, searchable help documentation " tabindex="-1" role="menuitem">NCBI Help Manual</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK1969/" title=" NCBI&#39;s monthly newsletter " tabindex="-1" role="menuitem">NCBI News</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed" title=" Biomedical literature abstracts " tabindex="-1" role="menuitem">PubMed</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/" title=" Free, full-text articles " tabindex="-1" role="menuitem">PubMed Central (PMC)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed/clinical" title=" Directory of PubMed queries about clinical topics " tabindex="-1" role="menuitem">PubMed Clinical Queries</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmedhealth/" title=" Reviews of clinical effectiveness research " tabindex="-1" role="menuitem">PubMed Health</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/literature/" tabindex="-1" role="menuitem">All Literature Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#proteins" tabindex="-1" role="menuitem" class="expandRight">Proteins</a><ul class="actual-resources-submenu proteins ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/proteinclusters" title=" Clusters of related proteins from prokaryotes and organelles " tabindex="-1" role="menuitem">Protein Clusters</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/protein" title=" Protein sequence data " tabindex="-1" role="menuitem">Protein Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/" title=" Curated nucleotide and protein sequences produced by NCBI " tabindex="-1" role="menuitem">Reference Sequence (RefSeq)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/proteins/" tabindex="-1" role="menuitem">All Proteins Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#sequence-analysis" tabindex="-1" role="menuitem" class="expandRight">Sequence Analysis</a><ul class="actual-resources-submenu sequence-analysis ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/sequence-analysis/" tabindex="-1" role="menuitem">All Sequence Analysis Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#taxonomy" tabindex="-1" role="menuitem" class="expandRight">Taxonomy</a><ul class="actual-resources-submenu taxonomy ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/taxonomy" title=" The NCBI taxonomy tree in Entrez " tabindex="-1" role="menuitem">Taxonomy</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Root" title=" Displays and links Entrez data to each taxonomic node " tabindex="-1" role="menuitem">Taxonomy Browser</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Taxonomy/CommonTree/wwwcmt.cgi" title=" Creates custom taxonomic trees " tabindex="-1" role="menuitem">Taxonomy Common Tree</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/taxonomy/" tabindex="-1" role="menuitem">All Taxonomy Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#training-tutorials" tabindex="-1" role="menuitem" class="expandRight">Training &amp; Tutorials</a><ul class="actual-resources-submenu training-tutorials ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/education/" title=" Central page providing links to tutorials and training materials " tabindex="-1" role="menuitem">NCBI Education Page</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK143764/" title=" Introductory articles about NCBI resources " tabindex="-1" role="menuitem">NCBI Handbook</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK3831/" title=" Online, searchable help documentation " tabindex="-1" role="menuitem">NCBI Help Manual</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK1969/" title=" NCBI&#39;s monthly newsletter " tabindex="-1" role="menuitem">NCBI News</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/training-tutorials/" tabindex="-1" role="menuitem">All Training &amp; Tutorials Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#variation" tabindex="-1" role="menuitem" class="expandRight">Variation</a><ul class="actual-resources-submenu variation ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/dbvar" title=" A database of genomic structural variation " tabindex="-1" role="menuitem">Database of Genomic Structural Variation (dbVar)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/snp" title=" Database of nucleotide sequence polymorphisms " tabindex="-1" role="menuitem">Database of Single Nucleotide Polymorphisms (dbSNP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/SNP/" title=" The SNP database tools page provides links to the general submission guidelines and to the submission handle request. " tabindex="-1" role="menuitem">SNP Submission Tool</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/variation/" tabindex="-1" role="menuitem">All Variation Resources...</a></li></ul></li></ul></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a><ul id="howto-submenu" class="ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/all/#howtos" tabindex="-1" role="menuitem">All How To</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/chemicals-bioassays/#howtos" tabindex="-1" role="menuitem">Chemicals &amp; Bioassays</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/dna-rna/#howtos" tabindex="-1" role="menuitem">DNA &amp; RNA</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/data-software/#howtos" tabindex="-1" role="menuitem">Data &amp; Software</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/domains-structures/#howtos" tabindex="-1" role="menuitem">Domains &amp; Structures</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genes-expression/#howtos" tabindex="-1" role="menuitem">Genes &amp; Expression</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genetics-medicine/#howtos" tabindex="-1" role="menuitem">Genetics &amp; Medicine</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genomes-maps/#howtos" tabindex="-1" role="menuitem">Genomes &amp; Maps</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/homology/#howtos" tabindex="-1" role="menuitem">Homology</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/literature/#howtos" tabindex="-1" role="menuitem">Literature</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/proteins/#howtos" tabindex="-1" role="menuitem">Proteins</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/sequence-analysis/#howtos" tabindex="-1" role="menuitem">Sequence Analysis</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/taxonomy/#howtos" tabindex="-1" role="menuitem">Taxonomy</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/training-tutorials/#howtos" tabindex="-1" role="menuitem">Training &amp; Tutorials</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/variation/#howtos" tabindex="-1" role="menuitem">Variation</a></li></ul></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2764168%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2764168%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" style="visibility: hidden;"><img src="./PMC2764168_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/82/">Antimicrob Agents Chemother</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/182333/">v.53(10); 2009 Oct</a></li><li class="accid">PMC2764168</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC2764168_files/logo-aac.gif" alt="Logo of aac" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="321,60,397,75" alt="Permissions" title="Permissions" href="http://journals.asm.org/misc/reprints.dtl" ref="reftype=publisher&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="398,60,500,75" alt="Journals.ASM.org" title="Journals.ASM.org" href="http://journals.asm.org/" ref="reftype=publisher&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="0,0,500,55" alt="Journal" title="Journal" href="http://aac.asm.org/" ref="reftype=publisher&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="48,60,118,75" alt="AAC Article" title="AAC Article" href="http://aac.asm.org/cgi/content/full/53/10/4385" ref="reftype=publisher&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7CArticle%7CFullText&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="119,60,195,75" alt="Journal Info" title="Journal Info" href="http://aac.asm.org/misc/about.dtl" ref="reftype=publisher&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="195,60,251,75" alt="Authors" title="Authors" href="http://aac.asm.org/misc/authors.dtl" ref="reftype=publisher&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="252,60,318,75" alt="Reviewers" title="Reviewers" href="http://aac.asm.org/misc/reviewers.dtl" ref="reftype=publisher&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Antimicrob Agents Chemother. 2009 Oct; 53(10): 43854392. </span></div><div><span class="fm-vol-iss-date">Published online 2009 Aug 10. </span>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1128%2FAAC.00449-09" target="pmc_ext" ref="reftype=other&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1128/AAC.00449-09</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2764168</span></div></div></div></div></div><h1 class="content-title">Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#fn2" rid="fn2" class=" fn"></a></sup> </h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Pham%20PA%5Bauth%5D">P. A. Pham</a>,<sup>1,</sup><sup>*</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=la%20Porte%20CJ%5Bauth%5D">C. J. L. la Porte</a>,<sup>2</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20LS%5Bauth%5D">L. S. Lee</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Heeswijk%20R%5Bauth%5D">R. van Heeswijk</a>,<sup>2,</sup><sup></sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Sabo%20JP%5Bauth%5D">J. P. Sabo</a>,<sup>3</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Elgadi%20MM%5Bauth%5D">M. M. Elgadi</a>,<sup>4</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Piliero%20PJ%5Bauth%5D">P. J. Piliero</a>,<sup>3</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Barditch-Crovo%20P%5Bauth%5D">P. Barditch-Crovo</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Fuchs%20E%5Bauth%5D">E. Fuchs</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Flexner%20C%5Bauth%5D">C. Flexner</a>,<sup>1</sup> and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Cameron%20DW%5Bauth%5D">D. W. Cameron</a><sup>2</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id1078728_ai" style="display:none"><div class="fm-affl" lang="en">Johns Hopkins University School of Medicine, Baltimore, Maryland,<sup>1</sup> University of Ottawa, The Ottawa Hospital and Ottawa Health Research Institute, Ottawa, Canada,<sup>2</sup> Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut,<sup>3</sup> Boehringer Ingelheim Canada, Ltd., Burlington, Ontario, Canada<sup>4</sup></div><div id="cor1"><sup>*</sup>Corresponding author. Mailing Address: 1830 East Monument St., Rm. 444, Baltimore, MD 21287. Phone: (410) 502-4342. Fax: (410) 955-7889. E-mail: <a href="mailto:dev@null" data-email="ude.imhj@mahpv" class="oemail">ude.imhj@mahpv</a></div><div id="fn1"><sup></sup>Present address: Tibotec BVBA, Mechelen, Belgium.</div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="pmctoggle" rid="id1078728_ai">Author information <span></span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="pmctoggle" rid="id1078728_an">Article notes <span></span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="pmctoggle" rid="id1078728_cpl">Copyright and License information <span></span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id1078728_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2009 Apr 3; Revised 2009 Jun 18; Accepted 2009 Aug 3.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id1078728_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>   2009, American Society for Microbiology</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid1035137" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid1035137title" style="text-transform: uppercase;">Abstract</h2><!--article-meta--><div><p id="__p3" class="p p-first-last">To identify pharmacokinetic (PK) drug-drug interactions between tipranavir-ritonavir (TPV/r) and rosuvastatin and atorvastatin, we conducted two prospective, open-label, single-arm, two-period studies. The geometric mean (GM) ratio was 1.37 (90% confidence interval [CI], 1.15 to 1.62) for the area under the concentration-time curve (AUC) for rosuvastatin and 2.23 (90% CI, 1.83 to 2.72) for the maximum concentration of drug in serum (<em>C</em><sub>max</sub>) for rosuvastatin with TPV/r at steady state versus alone. The GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of atorvastatin and 8.61 (90% CI, 7.25 to 10.21) for the <em>C</em><sub>max</sub> of atorvastatin with TPV/r at steady state versus alone. Tipranavir PK parameters were not affected by single-dose rosuvastatin or atorvastatin. Mild gastrointestinal intolerance, headache, and mild reversible liver enzyme elevations (grade 1 and 2) were the most commonly reported adverse drug reactions. Based on these interactions, we recommend low initial doses of rosuvastatin (5 mg) and atorvastatin (10 mg), with careful clinical monitoring of rosuvastatin- or atorvastatin-related adverse events when combined with TPV/r.</p></div></div><div id="__bodyid730210" class="tsec sec headless whole_rhythm"><p id="__p4" class="p p-first">Tipranavir coadministered with low-dose ritonavir (TPV/r) is an effective treatment option in treatment-experienced human immunodeficiency virus (HIV)-infected patients with resistance to more than one protease inhibitor (PI) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r9" rid="r9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638254" role="button" aria-expanded="false" aria-haspopup="true">9</a>). TPV/r is associated with adverse effects (AEs) that include increased triglycerides and cholesterol. NIAID Division of AIDS (DAIDS) grade 3 to 4 cholesterol elevation (&gt;400 mg/dl) and grade 3 to 4 triglyceride elevation (&gt;750 mg/dl) were higher in the TPV/r-treated patients than in the comparator-boosted PI-treated patients in phase III studies (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r9" rid="r9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638256" role="button" aria-expanded="false" aria-haspopup="true">9</a>). Grade 3 to 4 cholesterol elevation was 4.3 versus 0.6/100 patient exposure years, and triglyceride elevation was 27.8 versus 21.6/100 patient exposure years in the TPV/r versus comparator-boosted PI-treated patients. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study (N. Friis-Moller, P. Reiss, W. El-Sadr, A. D'Arminio Monforte, R. Thibaut, R. De Wit, S. Weber, E. Fontas, M. Law, A. Phillips, and the DAD Study Group, presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 5 to 8 February 2006) found a 16% increase in the relative risk of myocardial infarction in PI-treated patients. This association is possibly explained by dyslipidemia. Since the HIV-infected patient population is getting older, it is critical to control hyperlipidemia in PI-treated patients in order to reduce the risk of long-term cardiovascular complications. Potent 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (e.g., atorvastatin [Lipitor; Pfizer, Inc., New York, NY] and rosuvastatin [Crestor; AstraZeneca Pharmaceuticals, Wilmington, DE]) are recommended for the treatment of hypercholesterolemia (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r1" rid="r1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638230" role="button" aria-expanded="false" aria-haspopup="true">1</a>); however, their use in HIV-infected patients may be limited by clinically significant drug-drug interactions with PIs (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r5" rid="r5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638252" role="button" aria-expanded="false" aria-haspopup="true">5</a>). Atorvastatin is metabolized extensively by cytochrome P450 3A4 (CYP3A4) to metabolites that have in vitro inhibitory activity for HMG-CoA reductase similar to that of atorvastatin. Approximately 70% of the circulating inhibitory activity for HMG-CoA reductase has been attributed to these active metabolites (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r15" rid="r15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638236" role="button" aria-expanded="false" aria-haspopup="true">15</a>). Since TPV/r has a net inhibitory effect on CYP3A4 (M. Vourvahis, J. Dumond, K. Patterson, N. Rezk, N. White, S. Jennings, H. Tien, J. Sabo, T. MacGregor, and A. Kashuba, presented at the 14th Congress on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25 to 28 February 2007), it has the potential to significantly increase circulating atorvastatin concentrations.</p><p id="__p5" class="p">However, rosuvastatin is unlikely to interact with TPV/r since it is not a CYP3A4 substrate and it is not extensively metabolized (Crestor package insert; AstraZeneca Pharmaceuticals, Wilmington, DE). In order to provide guidance for clinical use, pharmacokinetic (PK) studies in healthy volunteers evaluated the drug-drug interactions between steady-state TPV/r and single-dose rosuvastatin (rosuvastatin study) and atorvastatin (atorvastatin study).</p></div><div id="__sec1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec1title" style="text-transform: uppercase;">MATERIALS AND METHODS</h2><div id="__sec2" class="sec sec-first"><p></p><h3 class="inline">Subjects. </h3><p id="__p6" class="p p-first-last">Each study protocol was approved by the local institutional review board, and written informed consent was obtained from all volunteers before enrollment in these studies.</p></div><div id="__sec3" class="sec"><p></p><h3 class="inline">Rosuvastatin study. </h3><p id="__p7" class="p p-first-last">HIV-negative healthy men and nonpregnant women volunteers 18 to 65 years old with body mass indexes of 18 to 30 kg/m<sup>2</sup> were enrolled in this study. Exclusion criteria included the use of any medications, herbal therapies, or grapefruit juice within 14 days before study entry or alcohol intake within 48 h before PK sampling days, active hepatitis B or C infection, and significant laboratory abnormalities. All women were required to have a negative pregnancy test result at study entry and were instructed to use a barrier contraceptive method during the study period.</p></div><div id="__sec4" class="sec"><p></p><h3 class="inline">Atorvastatin study. </h3><p id="__p8" class="p p-first-last">Healthy men and women volunteers 18 to 60 years old, with body mass indexes of 18 to 29 kg/m<sup>2</sup>, were eligible for this study. Subjects were considered to be healthy based on their medical histories, physical examination, electrocardiogram, urinalysis, routine tests of biochemistry and hematology, hepatitis B and C status, and HIV status. Throughout the study period, subjects were instructed to abstain from alcohol, grapefruits/grapefruit juice (starting 10 days prior to the first study day), Seville oranges, and over-the-counter herbal medications (garlic supplements, St. John's wort, milk thistle) starting 5 days prior to the first study day. Methylxanthine-containing foods or drinks were not allowed within 72 h prior to and during PK sampling days.</p></div><div id="__sec5" class="sec"><p></p><h3 class="inline">Study design and procedures. (i) Rosuvastatin study. </h3><p id="__p9" class="p p-first-last">This was a prospective, open-label, single-arm, inpatient, steady-state PK study. Subjects received a single 10-mg dose of rosuvastatin on day 1, followed by tipranavir 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to 13), with a single 10-mg dose of rosuvastatin given on day 12. All study drug doses were given under direct observation by the nursing staff of the Johns Hopkins University General Clinical Research Center. All subjects received 100% of study medications. Intensive PK sampling was performed on days 1 to 3 (before the addition of TPV/r) and days 12 to 14 (with TPV/r at steady state) for rosuvastatin and days 12 and 13 for tipranavir and ritonavir. A standard 670-kcal (33% fat) breakfast was served to subjects within 30 min before morning medication administration. No caffeine or food was allowed until 5 h postdose. No grapefruit juice was allowed on PK sampling days. Blood samples were collected at the following time points: 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for tipranavir and ritonavir and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h postdose for rosuvastatin. A pharmacokinetic comparison of single-dose rosuvastatin with single-dose rosuvastatin coadministered with TPV/r 500 mg/200 mg twice daily at steady state was undertaken. The short-term safety and steady-state PKs of tipranavir and ritonavir coadministered with single-dose rosuvastatin (10 mg) were also evaluated.</p></div><div id="__sec6" class="sec"><p></p><h3 class="inline">(ii) Atorvastatin study. </h3><p id="__p10" class="p p-first">The single-dose PKs of atorvastatin, orthohydroxy atorvastatin, and parahydroxy atorvastatin were assessed on day 1 after ingestion of 40 mg of atorvastatin alone. From days 14 to 21, subjects received TPV/r 500 mg/200 mg twice daily. TPV/r dosages from the evening of day 13 to the morning of day 18 were taken at home. All dosages before and after this period were taken as directly observed therapy. Subjects were asked to log their adherence to study medications. All subjects had 100% adherence with study medication. The steady-state PKs of tipranavir were assessed on day 19 after ingestion of TPV/r alone and on day 20 after administration of TPV/r 500 mg/200 mg twice daily plus a single dose of atorvastatin 10 mg, as an increase in atorvastatin concentrations was expected in combination with steady-state TPV/r at 500 mg/200 mg twice daily. Blood samples for analysis of atorvastatin and hydroxy metabolites were collected on days 1 and 20 in EDTA-containing tubes by an indwelling catheter or the venipuncture of a forearm vein just before and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of atorvastatin (14 samples).</p><p id="__p11">Blood samples for analysis of tipranavir concentrations were collected in heparinized tubes on days 19 and 20 by an indwelling catheter or the venipuncture of a forearm vein just before and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h after ingestion of TPV/r (12 samples). Ritonavir plasma concentrations were not measured in this study.</p><p id="__p12">On PK sampling days, atorvastatin and TPV/r were administered orally at 8 a.m. with 240 ml of water after an overnight fast. A light snack (i.e., 240 ml of low-fat milk and dry bread) was allowed at no less than 1 h prior to dosing or 2 h after dosing to minimize nausea and vomiting if necessary. Subjects were kept in an upright position for the first 2 h after drug administration. A standardized lunch and dinner were served at 4 and 10 h after the morning dose, respectively (500 to 682 kcal; 23% to 25% from fat). The total daily fluid intake was restricted to a maximum of 3 liters.</p><p id="__p13" class="p p-last">Subject safety was monitored by an assessment of all AEs at each visit, in addition to a laboratory assessment of safety parameters.</p></div><div id="__sec7" class="sec"><p></p><h3 class="inline">Bioanalysis. (i) Rosuvastatin assay. </h3><p id="__p14" class="p p-first">A bioanalytic method has been developed and validated by PPD (Richmond, VA) for the analysis of rosuvastatin in human plasma containing dipotassium EDTA. A 200-l-sample aliquot was fortified with 200 l of internal standard (IS) working solution. Analytes were isolated by protein precipitation with 400 l of acetonitrile. Sample extraction steps were controlled and automated using a Quadra 96 model 320 (Tomtec, Hamden, CT). The supernatant was transferred to another plate and evaporated to dryness under a nitrogen stream at 45C to 50C. The remaining residue was reconstituted with 150 l of 20:80:0.1 acetonitrile-water-formic acid (vol/vol/vol). The final extract was analyzed via high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) detection.</p><p id="__p15" class="p p-last">Eight calibration standards were analyzed in duplicate over the nominal concentration range of 0.100 to 100 ng/ml. For this validation, the lower limit of quantitation was nominally 0.100 ng/ml for rosuvastatin.</p></div><div id="__sec8" class="sec"><p></p><h3 class="inline">(ii) Atorvastatin assay. </h3><p id="__p16" class="p p-first-last">Plasma concentrations of atorvastatin and its hydroxy metabolites were measured by validated liquid chromatography (LC)-MS-MS at MDS Pharma Services (Saint-Laurent, Quebec, Canada). The respective deuterated analogs of the analytes were used as ISs. Briefly, the analytes were extracted from 200 l of EDTA plasma by solid-phase extraction using C<sub>8</sub> cartridges. After isolation and evaporation to dryness, the analytes were reconstituted and 200 l was injected for LC-MS-MS analysis. The analytes were separated on a Luna C<sub>8</sub> column (Phenomenex, Torrance, CA) and quantified by MS under multiple-reaction monitoring mode. The lower limits of quantitation were 0.225 ng/ml for atorvastatin, 0.250 ng/ml for parahydroxy atorvastatin, and 0.175 ng/ml for orthohydroxy atorvastatin using a 200-l sample.</p></div><div id="__sec9" class="sec"><p></p><h3 class="inline">(iii) Tipranavir assay. </h3><p id="__p17" class="p p-first">A validated HPLC-MS-MS method was used to measure plasma drug concentrations of tipranavir and ritonavir (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r16" rid="r16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638245" role="button" aria-expanded="false" aria-haspopup="true">16</a>). In general terms, ritonavir, tipranavir, and an IS are extracted from EDTA human plasma by a two-step liquid-liquid extraction using an ethyl acetate-hexane mixture followed by a hexane wash. The analytes are separated and detected by an LC-MS-MS system utilizing a 2.0- by 30-mm Synergi Polar RP column (Phenomenex) with a formic acid-acetic acid-acetonitrile mobile phase. For the atorvastatin study, tipranavir and an IS (PNU-109011) were extracted from 50 l of heparinized plasma by liquid-liquid extraction using 600 l of a mixture of ethyl acetate-hexane (9/1 [vol/vol]) after the addition of 100 l of borate buffer (pH 9).</p><p id="__p18" class="p p-last">High and low calibration ranges were used to predict unknown concentrations. The high calibration curve ranged from 20,000 ng/ml to 1,000 ng/ml. The low calibration curve ranged from 2,000 ng/ml to 25.0 ng/ml.</p></div><div id="__sec10" class="sec"><p></p><h3 class="inline">Data analysis and statistical methods. (i) PK analysis. </h3><p id="__p19" class="p p-first-last">For both studies, noncompartmental methods were used for PK analysis (WinNonlin versions 5.01 and 4.0; Pharsight Corporation, Mountain View, CA). The highest observed plasma concentration was defined as the maximum concentration of drug in serum (<em>C</em><sub>max</sub>), with the corresponding sampling time to <em>C</em><sub>max</sub> (<em>T</em><sub>max</sub>). The elimination rate constant (z) was determined by least squares linear regression analysis (log <em>C</em> versus <em>t</em>) of the last data points (<em>n</em>  3). The half-life (<em>t</em><sub>1/2</sub>) was calculated by the equation <em>t</em><sub>1/2</sub> = ln2/z. After single-dose administration, the area under the concentration-time curve from 0 h to infinity (AUC<sub>0-</sub>) was calculated using the linear-log trapezoidal rule (linear up/log down) from zero to the last measured concentration, with extrapolation to infinity by dividing the last measured concentration by z (<em>C</em><sub>last</sub>/<em>z</em>). The AUC<sub>0-12</sub> was estimated using the linear-log trapezoidal rule (linear up/log down). The concentration at 12 h postdose was defined as <em>C</em><sub>12</sub>. The CL/<em>F</em>, where <em>F</em> represents the oral bioavailability, was calculated as dose/AUC, and the volume of distribution (<em>V</em>) was calculated as (CL/<em>F</em>)/<em>z</em>.</p></div><div id="__sec11" class="sec sec-last"><p></p><h3 class="inline">(ii) Statistical analysis. </h3><p id="__p20" class="p p-first">Statistical analysis was performed with SAS (version 8.01; SAS Institute, Inc., Cary, NC) and Stata (version 8; Stata Corp., College Park, TX). Statistical comparisons were performed after logarithmic transformation. Summary statistics for each of the PK parameters were tabulated by regimen and study day. Geometric mean (GM) ratios and corresponding 90% confidence intervals (CI) of PK parameters were calculated. The lack of a clinically relevant interaction was declared if the 90% CI of the GM ratio was completely contained in the acceptance range of 0.80 to 1.25.</p><p id="__p21">Prior to statistical analysis of the effect of TPV/r on atorvastatin (day 1 versus day 20), the atorvastatin AUC<sub>0-</sub> and <em>C</em><sub>max</sub> were multiplied by 4 to adjust for the difference in atorvastatin dose between day 1 (40 mg) and day 20 (10 mg). No dose adjustments were made for the analysis of the hydroxy metabolite concentrations.</p><p id="__p22">In addition to the analysis of atorvastatin and its hydroxy metabolites individually, the effect on total HMG-CoA reductase inhibitory activity was assessed. The total HMG-CoA reductase inhibitory activity was calculated as the sum of the time-specific molar concentrations of atorvastatin (normalized for a 40-mg dose), orthohydroxy atorvastatin, and parahydroxy atorvastatin.</p><p id="__p23">Nonparametric tests were used for comparisons between PK parameters (Mann-Whitney U test or Wilcoxon signed-rank test as appropriate). Spearman's correlation was used to test for associations between continuous variables. A <em>P</em> value of &lt;0.05 was considered statistically significant for all comparisons. The within-subject variability in the steady-state tipranavir AUC<sub>0-12</sub> was calculated as the percent difference between the individual tipranavir AUC<sub>0-12</sub> values on day 19 and day 20.</p><p id="__p24" class="p p-last">For sample size calculations in both studies, it was assumed that the coefficient of variation (CV) would range from 20% to 40% for the AUCs of rosuvastatin and atorvastatin. Therefore, a sample size of 20 would provide &gt;90% power to detect a 25% change in the AUCs of rosuvastatin and atorvastatin.</p></div></div><div id="__sec12" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec12title" style="text-transform: uppercase;">RESULTS</h2><div id="__sec13" class="sec sec-first"><p></p><h3 class="inline">Rosuvastatin study. (i) Subjects. </h3><p id="__p25" class="p p-first-last">Of the 29 subjects (5 women, 24 men), 16 evaluable subjects completed the study. The population was mostly African-American (76%), with a median age of 42 (range, 18 to 64) years, a median weight of 78 (range, 51 to 96) kg, and a median height of 175 (range, 162 to 196) cm. No Asian-Americans participated in the study.</p></div><div id="__sec14" class="sec"><p></p><h3 class="inline">(ii) Interaction between TPV/r and rosuvastatin. </h3><p id="__p26" class="p p-first-last">With TPV/r coadministration, the GM AUC for rosuvastatin was 38.6 ngh/ml, a 37% increase compared with that of rosuvastatin alone (<em>P</em> = 0.0006) (Fig. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.1</span></span><span>1</span></a> and <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f2/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="f2" rid-ob="ob-f2" co-legend-rid="lgnd_f2"><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -1.5em;">and2).</span></span><span>2</span></a>). The GM <em>C</em><sub>max</sub> for rosuvastatin was 5.78 ng/ml with TPV/r coadministration, a 123% increase compared with that of rosuvastatin alone (<em>P</em> &lt; 0.001) (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t1/" target="true" class="fig-table-link table figpopup" rid-figpopup="t1" rid-ob="ob-t1" co-legend-rid=""><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). Rosuvastatin clearance (CL) also was decreased by 27% with TPV/r coadministration; this resulted in a significant increase in plasma <em>t</em><sub>1/2</sub> (20.6 h versus 9.01 h; <em>P</em> &lt; 0.001). Tipranavir and ritonavir PK parameters were not affected by single-dose rosuvastatin (see Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t3/" target="true" class="fig-table-link table figpopup" rid-figpopup="t3" rid-ob="ob-t3" co-legend-rid=""><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -2.5em;">Table3</span></span><span>3</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="f1" co-legend-rid="lgnd_f1"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f1/" target="figure" rid-figpopup="f1" rid-ob="ob-f1"><img src="./PMC2764168_files/zac0100984920001.gif" class="small-thumb" alt="FIG. 1." title="FIG. 1." src-large="/pmc/articles/PMC2764168/bin/zac0100984920001.jpg"></a><div class="icnblk_cntnt" id="lgnd_f1"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f1/" target="figure" rid-figpopup="f1" rid-ob="ob-f1">FIG. 1.</a></div><!--caption a4--><div><span>Plasma rosuvastatin concentration-time profile in the absence (open circles) and presence (filled circles) of steady-state TPV/r.</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="f2" co-legend-rid="lgnd_f2"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f2/" target="figure" rid-figpopup="f2" rid-ob="ob-f2"><img src="./PMC2764168_files/zac0100984920002.gif" class="small-thumb" alt="FIG. 2." title="FIG. 2." src-large="/pmc/articles/PMC2764168/bin/zac0100984920002.jpg"></a><div class="icnblk_cntnt" id="lgnd_f2"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f2/" target="figure" rid-figpopup="f2" rid-ob="ob-f2">FIG. 2.</a></div><!--caption a4--><div><span>Effect of steady-state TPV/r on single-dose rosuvastatin (ROS) <em>C</em><sub>max</sub>, plasma drug concentration at 24 h (Cp<sub>24h</sub>), and AUC<sub>0-24</sub>.</span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="t1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t1/" target="table" rid-ob="ob-t1" rid-figpopup="t1" class="table img_link icnblk_img figpopup"><img alt="TABLE 1." title="TABLE 1." class="small-thumb" src="./PMC2764168_files/saved_resource" src-large="/pmc/articles/PMC2764168/table/t1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t1/" target="table" rid-figpopup="t1" rid-ob="ob-t1">TABLE 1.</a></div><!--caption a4--><div><span>PK parameters of rosuvastatin alone or rosuvastatin plus TPV/r<sup><em>a</em></sup></span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="t3"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t3/" target="table" rid-ob="ob-t3" rid-figpopup="t3" class="table img_link icnblk_img figpopup"><img alt="TABLE 3." title="TABLE 3." class="small-thumb" src="./PMC2764168_files/saved_resource(1)" src-large="/pmc/articles/PMC2764168/table/t3/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t3/" target="table" rid-figpopup="t3" rid-ob="ob-t3">TABLE 3.</a></div><!--caption a4--><div><span>Effect of rosuvastatin (<em>n</em> = 16) and atorvastatin (<em>n</em> = 22) on the PK of TPV/r<sup><em>a</em></sup></span></div></div></div></div><div id="__sec15" class="sec"><p></p><h3 class="inline">(iii) Safety. </h3><p id="__p27" class="p p-first-last">The most common AEs associated with study drug administration were diarrhea (10.3%), nausea (13.8%), abdominal cramps (10.3%), flatulence (10.3%), headache (13.8%), and grade 1 liver enzyme elevations (34.5%) not resulting in study drug discontinuation. With the exception of one grade 2 nausea, one grade 2 rash, and eight grade 2 to 3 liver enzyme elevations, all AEs were of mild intensity (grade 1). Of 29 subjects enrolled, 13 subjects did not complete the study. Eight subjects discontinued because of grade 2 to 3 liver enzyme elevations, which were reversible upon study drug discontinuation. None of the subjects who had an increase in liver enzyme levels developed signs or symptoms of clinical hepatitis. One subject withdrew because of a grade 3 hypersensitivity reaction (mild shortness of breath, diffuse rash, and liver enzyme elevations). Three subjects withdrew consent, and one subject was administratively discharged due to a positive drug screen. The frequency and severity of these AEs are consistent with those observed in clinical trials involving HIV-infected patients treated with TPV/r. The rate of discontinuation in this study was high due to a lower threshold for study drug discontinuation (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r9" rid="r9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638234" role="button" aria-expanded="false" aria-haspopup="true">9</a>). The potential for increased risk of hepatotoxicity with the coadministration of TPV/r plus rosuvastatin could not be assessed since all liver enzyme elevations occurred before coadministration began (day 8). All AEs resolved with study drug discontinuation.</p></div><div id="__sec16" class="sec"><p></p><h3 class="inline">Atorvastatin study. (i) Subjects. </h3><p id="__p28" class="p p-first-last">Twenty-three subjects (11 men, 12 women) were recruited into this study. The population was mostly white (95.7%), with a median age of 32 (range, 18 to 55) years, a median weight of 72 (range, 55 to 99) kg, and a median height of 168 (range, 158 to 189) cm. The atorvastatin PK results from one subject and the steady-state tipranavir PK results from another subject were excluded from all statistical analyses because of nonphysiologic results (more than fivefold increase in drug concentration at the end of the dosing interval). However, the outcome of the study was not different with or without the data from these subjects (data not shown).</p></div><div id="__sec17" class="sec"><p></p><h3 class="inline">(ii) Interaction between TPV/r and atorvastatin. </h3><p id="__p29" class="p p-first">TPV/r increased the dose-adjusted atorvastatin AUC<sub>0-</sub> and <em>C</em><sub>max</sub> by approximately ninefold (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t2/" target="true" class="fig-table-link table figpopup" rid-figpopup="t2" rid-ob="ob-t2" co-legend-rid=""><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -3em;">(Table2;</span></span><span>2</span></a>; Fig. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f3/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="f3" rid-ob="ob-f3" co-legend-rid="lgnd_f3"><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -2em;">Fig.3</span></span><span>3</span></a> and <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f4/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="f4" rid-ob="ob-f4" co-legend-rid="lgnd_f4"><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -1.5em;">and4).</span></span><span>4</span></a>). As both apparent CL/<em>F</em> and apparent <em>V</em>/<em>F</em> were decreased almost proportionally, there was no effect on the <em>t</em><sub>1/2</sub> of atorvastatin. TPV/r inhibited the formation of orthohydroxy and parahydroxy atorvastatin and reduced the AUC<sub>0-</sub> by 89% (<em>P</em> = 0.002) and 82% (<em>P</em> = 0.001), respectively. Total HMG-CoA reductase inhibitory activity increased by approximately fourfold in the presence of TPV/r. The GM ratios for the AUC<sub>0-</sub> and <em>C</em><sub>max</sub> of the total HMG-CoA reductase inhibitory activity were 3.87 (90% CI, 3.13 to 4.33; <em>P</em> &lt; 0.001) and 4.97 (90% CI, 3.71 to 5.51; <em>P</em> &lt; 0.001), respectively.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="f3" co-legend-rid="lgnd_f3"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f3/" target="figure" rid-figpopup="f3" rid-ob="ob-f3"><img src="./PMC2764168_files/zac0100984920003.gif" class="small-thumb" alt="FIG. 3." title="FIG. 3." src-large="/pmc/articles/PMC2764168/bin/zac0100984920003.jpg"></a><div class="icnblk_cntnt" id="lgnd_f3"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f3/" target="figure" rid-figpopup="f3" rid-ob="ob-f3">FIG. 3.</a></div><!--caption a4--><div><span>Plasma drug concentration (Cp)-time profiles for atorvastatin (A), orthohydroxy atorvastatin (B), and parahydroxy atorvastatin (C). Shown are 40 mg atorvastatin alone (open circles) (A to C), 10 mg atorvastatin plus steady-state TPV/r (closed circles)</span> <strong>...</strong></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="f4" co-legend-rid="lgnd_f4"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f4/" target="figure" rid-figpopup="f4" rid-ob="ob-f4"><img src="./PMC2764168_files/zac0100984920004.gif" class="small-thumb" alt="FIG. 4." title="FIG. 4." src-large="/pmc/articles/PMC2764168/bin/zac0100984920004.jpg"></a><div class="icnblk_cntnt" id="lgnd_f4"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/figure/f4/" target="figure" rid-figpopup="f4" rid-ob="ob-f4">FIG. 4.</a></div><!--caption a4--><div><span>Effect of steady-state TPV/r on single-dose atorvastatin (ATO) <em>C</em><sub>max</sub>, plasma drug concentration (Cp), and AUC<sub>0-</sub>.</span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="t2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t2/" target="table" rid-ob="ob-t2" rid-figpopup="t2" class="table img_link icnblk_img figpopup"><img alt="TABLE 2." title="TABLE 2." class="small-thumb" src="./PMC2764168_files/saved_resource(2)" src-large="/pmc/articles/PMC2764168/table/t2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t2/" target="table" rid-figpopup="t2" rid-ob="ob-t2">TABLE 2.</a></div><!--caption a4--><div><span>Single-dose PK parameters of atorvastatin, orthohydroxy atorvastatin, and parahydroxy atorvastatin after administration of atorvastatin 40 mg alone and coadministration of atorvastatin 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (<em>n</em> =</span> <strong>...</strong></div></div></div><p id="__p30" class="p p-last">Single-dose atorvastatin did not affect the steady-state PKs of tipranavir (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/table/t3/" target="true" class="fig-table-link table figpopup" rid-figpopup="t3" rid-ob="ob-t3" co-legend-rid=""><span style="position: relative;text-decoration:none;"><span class="figpopup-sensitive-area" style="left: -3em;">(Table3</span></span><span>3</span></a>).</p></div><div id="__sec18" class="sec sec-last"><p></p><h3 class="inline">(iii) Safety. </h3><p id="__p31" class="p p-first">In general, treatment with TPV/r 500 mg/200 mg twice daily alone and in the presence of single-dose atorvastatin was well tolerated in this study. There were no study discontinuations due to AEs or for any other reason. One serious AE was reported in this study (a sprained ankle due to exercise), which was unrelated to the study drugs.</p><p id="__p32">The most frequently reported AEs during all treatment phases were related to the gastrointestinal tract (<em>n</em> = 22 [95.7%]), followed by the nervous system (<em>n</em> = 16 [69.6%]). During treatment with TPV/r alone, 17 (73.9%) subjects reported diarrhea, 11 (47.8%) reported nausea, and 9 (39.1%) reported abdominal pain. Flatulence, loose stools, and dyspepsia occurred in six (26.1%), five (21.7%), and three (13%) subjects, respectively, during treatment with TPV/r. With the exception of one case of moderate nausea, all gastrointestinal events were of mild intensity and rarely required treatment intervention. Headache and dysgeusia were reported by eight (34.8%) and four (17.4%) subjects, respectively, during treatment with TPV/r.</p><p id="__p33" class="p p-last">With the exception of one subject with an asymptomatic DAIDS grade 3 elevation in alanine aminotransferase, there were no clinically relevant changes (grade 3 or higher) in any of the laboratory tests. The largest deviations from the median baseline were observed for triglycerides and alanine aminotransferase levels, which increased by 1.7-fold and 3.1-fold, respectively, relative to the baseline.</p></div></div><div id="__sec19" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec19title" style="text-transform: uppercase;">DISCUSSION</h2><p id="__p34" class="p p-first">A PK drug interaction was predicted to be unlikely to occur between rosuvastatin and TPV/r since rosuvastatin is not a known substrate, inhibitor, or inducer of CYP3A4. Furthermore, rosuvastatin is not extensively metabolized, with approximately 10% of a radiolabeled dose recovered as <em>N</em>-desmethyl rosuvastatin. This major metabolite is formed principally by CYP2C9 (Crestor package insert; AstraZeneca Pharmaceuticals, Wilmington, DE). Although in vitro studies indicate that tipranavir is an inhibitor of CYP2C9, an in vivo cocktail study determined that the steady-state levels of tipranavir (500 mg) plus ritonavir 200 mg twice daily did not affect concentrations of plasma <em>S</em>-warfarin, a CYP2C9 substrate (M. Vourvahis, presented at the Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, 16 to 18 April 2007). When TPV/r was coadministered with rosuvastatin at steady state, the AUC<sub>0-</sub> and <em>C</em><sub>max</sub> of rosuvastatin were increased by 37% and 123%, respectively, after single-dose rosuvastatin. Similarly, concomitant administration of steady-state TPV/r significantly increased the AUC<sub>0-</sub> of atorvastatin. However, the atorvastatin AUC increase was significantly higher. The differential effect of TPV/r on the PKs of rosuvastatin and atorvastatin may be due to the difference in the mechanisms of interaction.</p><p id="__p35">Rosuvastatin is not a P-glycoprotein (Pgp) substrate, but it is a substrate of organic anion-transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP), also known as ATP-binding cassette transporter G2 (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r12" rid="r12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638239" role="button" aria-expanded="false" aria-haspopup="true">12</a>). OATP1B1 is located at the basolateral membrane of hepatocytes and functions as an influx transporter to facilitate the entry of drugs into hepatocytes. These types of substrates include several statins (i.e., pravastatin, cerivastatin, atorvastatin, and rosuvastatin) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r7" rid="r7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638237" role="button" aria-expanded="false" aria-haspopup="true">7</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r10" rid="r10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638248" role="button" aria-expanded="false" aria-haspopup="true">10</a>). BCRP is expressed in many tissue barriers throughout the body, including the epithelium of the small intestine, liver canalicular membrane ducts, placental syncytiotrophoblasts, and lobules of the breast (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r4" rid="r4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638229" role="button" aria-expanded="false" aria-haspopup="true">4</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r17" rid="r17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638249" role="button" aria-expanded="false" aria-haspopup="true">17</a>). In the gastrointestinal tract, BCRP is localized in the apical membrane of the intestinal epithelia, with the highest BCRP mRNA expression in the duodenum (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r6" rid="r6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638241" role="button" aria-expanded="false" aria-haspopup="true">6</a>). Unlike OATP1B1, BCRP generally functions as an efflux transporter that facilitates hepatobiliary excretion and decreases intestinal absorption of BCRP substrates. The marked effect on the oral bioavailability of BCRP substrates was demonstrated in a BCRP 1 knockout murine model. The plasma concentrations of nitrofurantoin, a substrate of BCRP, were increased by fourfold and twofold compared with those in wild-type mice after oral and intravenous administration, respectively (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r20" rid="r20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638257" role="button" aria-expanded="false" aria-haspopup="true">20</a>). Similarly, BCRP (ATP-binding cassette transporter G2) polymorphism (c.421AA genotype) in healthy volunteers was associated with significant increased atorvastatin and rosuvastatin AUC values of 72% and 100%, respectively (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r13" rid="r13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638262" role="button" aria-expanded="false" aria-haspopup="true">13</a>). Cyclosporine, an OATP1B1 and BCRP inhibitor, significantly increases rosuvastatin and atorvastatin serum concentrations, by 11-fold and 8-fold, respectively (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r8" rid="r8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638242" role="button" aria-expanded="false" aria-haspopup="true">8</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r24" rid="r24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638233" role="button" aria-expanded="false" aria-haspopup="true">24</a>). Tipranavir, ritonavir, and lopinavir are also BCRP inhibitors in vitro (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r19" rid="r19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638240" role="button" aria-expanded="false" aria-haspopup="true">19</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r27" rid="r27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638244" role="button" aria-expanded="false" aria-haspopup="true">27</a>). Concentration-dependent inhibition of [<sup>3</sup>H]estradiol-17-<span class="small-caps">d</span>-glucuronide uptake by ritonavir is also observed in OATP1B1-transfected HeLa cells and OATP-mediated CGamF (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r25" rid="r25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638247" role="button" aria-expanded="false" aria-haspopup="true">25</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r28" rid="r28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638235" role="button" aria-expanded="false" aria-haspopup="true">28</a>). The potential mechanism of interaction in this study may be the result of dual inhibition of OATP1B1 and BCRP transporters by ritonavir and tipranavir. Inhibition of OATP1B1 may lead to a decrease in hepatocyte uptake of rosuvastatin and atorvastatin, whereas inhibition of BCRP decreases hepatobiliary excretion and increases rosuvastatin and atorvastatin absorption.</p><p id="__p36">In addition to OATP1B1 and BCRP transporter-mediated interaction, inhibition of first-pass metabolism of atorvastatin, rather than inhibition of its systemic metabolism, may explain the 8.6-fold increase in atorvastatin <em>C</em><sub>max</sub> (an 8.6-fold increase) without an effect on the <em>t</em><sub>1/2</sub>. The absolute oral bioavailability of atorvastatin is low (14%), which is likely a result of the combined effects of intestinal metabolism by CYP3A4 and transport into the gut lumen by the multidrug efflux transporter Pgp (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r4" rid="r4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638246" role="button" aria-expanded="false" aria-haspopup="true">4</a>). Assuming the linear PKs of atorvastatin (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r23" rid="r23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638259" role="button" aria-expanded="false" aria-haspopup="true">23</a>), coincidentally, the formation of orthohydroxy and parahydroxy atorvastatin was inhibited. The AUC<sub>0-</sub> values of these metabolites were reduced by 89% and 82%, respectively, in the presence of TPV/r. Steady-state TPV/r has an inhibitory effect on CYP3A4/5 but minimal effects on Pgp (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r5" rid="r5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638250" role="button" aria-expanded="false" aria-haspopup="true">5</a>) and may thus increase the bioavailability of atorvastatin, as suggested in the current study. Previous studies have reported an increased bioavailability of various CYP3A4 and/or Pgp substrates in the presence of ritonavir (e.g., digoxin and saquinavir) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r22" rid="r22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638231" role="button" aria-expanded="false" aria-haspopup="true">22</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r26" rid="r26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638261" role="button" aria-expanded="false" aria-haspopup="true">26</a>). Similarly near-complete absorption of atorvastatin in the presence of TPV/r (<em>F</em>  100%) may explain the observed changes in the AUC<sub>0-</sub> and <em>C</em><sub>max</sub>, the delayed <em>T</em><sub>max</sub>, and the proportional reduction in both the CL/<em>F</em> and the <em>V</em>/<em>F</em>, resulting in no change in the <em>t</em><sub>1/2</sub>. On the other hand, the rosuvastatin <em>t</em><sub>1/2</sub> was increased by approximately twofold. This finding suggests that alternative metabolic pathways for rosuvastatin may be present.</p><p id="__p37">These findings are consistent with those of drug interaction studies evaluating the effect of another PI, lopinavir-ritonavir (LPV/r), when coadministered with rosuvastatin at steady state. A prospective study conducted with healthy volunteers found that rosuvastatin AUC<sub>0-</sub> and <em>C</em><sub>max</sub> were increased 2.1- and 4.7-fold, respectively, when coadministered with LPV/r (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r14" rid="r14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638255" role="button" aria-expanded="false" aria-haspopup="true">14</a>). Similar to the results of the current atorvastatin study, the <em>t</em><sub>1/2</sub> was not affected; however, the magnitude of the drug interaction observed between rosuvastatin and LPV/r was severalfold higher. This effect may be due to the higher inhibitory potency of BCRP observed with lopinavir in vitro (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r27" rid="r27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638258" role="button" aria-expanded="false" aria-haspopup="true">27</a>). Coadministration of atazanavir-ritonavir with rosuvastatin was found to result in a 210% increase in the rosuvastatin AUC; however, no significant interaction was observed with fosamprenavir-ritonavir (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r2" rid="r2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638251" role="button" aria-expanded="false" aria-haspopup="true">2</a>). The lack of interaction observed with fosamprenavir-ritonavir may be due to its low BCRP and OATP1B1 inhibitory potential (V. E. Theil-Demby, K. Harmon, M. Naqwe, J. Humphreys, M. B. Wire, and J. W. Polli, presented at the 2008 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists [AAPS], November 2008). Increased exposure to atorvastatin has previously been observed in combination with other HIV PIs, which are all substrates/inhibitors of CYP3A4. Coadministration with LPV/r 400 mg/100 mg twice daily increased the atorvastatin (20 mg once daily) AUC<sub>0-24</sub> and <em>C</em><sub>max</sub> by 5.9- and 4.7-fold, respectively, and increased the AUC<sub>0-24</sub> and <em>C</em><sub>max</sub> of the total HMG-CoA reductase inhibitory activity by 2.5- and 4.5-fold, respectively (R. A. Carr, A. K. Andre, and R. J. Bertz, presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 17 to 20 September 2000) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r5" rid="r5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638228" role="button" aria-expanded="false" aria-haspopup="true">5</a>). The combination of saquinavir-ritonavir 400 mg/400 mg twice daily increased the median atorvastatin (40 mg) AUC<sub>0-24</sub> by 3.5-fold and the AUC<sub>0-24</sub> of the total HMG-CoA reductase inhibitory activity by 1.8-fold (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r5" rid="r5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638232" role="button" aria-expanded="false" aria-haspopup="true">5</a>). Nelfinavir, a moderately strong inhibitor of CYP3A4, increased the AUC<sub>0-24</sub> and <em>C</em><sub>max</sub> of the total HMG-CoA reductase inhibitory activity by 1.7- and 2.2-fold, respectively, after administration of atorvastatin 10 mg once daily for 14 days (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r11" rid="r11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638260" role="button" aria-expanded="false" aria-haspopup="true">11</a>). The combination of darunavir-ritonavir 300 mg/100 mg twice daily with atorvastatin 10 mg daily resulted in an AUC<sub>0-24</sub> that was 15% lower than the AUC<sub>0-24</sub> of atorvastatin 40 mg daily alone, suggesting an almost fourfold increase in the atorvastatin AUC<sub>0-24</sub> (R. M. W. Hoetelmans, A. Lasure, A. Koester, M. de Pauw, B. van Baelen, M. Peeters, W. Parys, and E. Lefebvre, presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 30 October to 2 November 2004).</p><p id="__p38">One of the most serious AEs associated with HMG-CoA reductase inhibitors (statins) is rhabdomyolysis, which can result in significant morbidity and mortality (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r21" rid="r21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638253" role="button" aria-expanded="false" aria-haspopup="true">21</a>). Although rhabdomyolysis may occur in 0.1% to 0.5% of the population when statins are prescribed as monotherapy, the risk is greatly increased when drugs that inhibit CYP3A4-mediated metabolism are used concomitantly (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r21" rid="r21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638238" role="button" aria-expanded="false" aria-haspopup="true">21</a>). Several cases of atorvastatin-associated rhabdomyolysis have been reported in patients using atorvastatin in combination with CYP3A4 inhibitors, such as cyclosporine or delavirdine (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r3" rid="r3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_322919664" role="button" aria-expanded="false" aria-haspopup="true">3</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r18" rid="r18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_183638243" role="button" aria-expanded="false" aria-haspopup="true">18</a>). Although the safety and efficacy of rosuvastatin and atorvastatin could not be assessed by these single-dose studies, to minimize the risk of rhabdomyolysis, careful monitoring for any signs or symptoms of toxicity is recommended. Alternatively, statins with a lower likelihood of interactions could be considered.</p><p id="__p39" class="p p-last">In conclusion, we observed a clinically relevant increase in rosuvastatin and atorvastatin concentrations during coadministration of TPV/r 500 mg/200 mg twice daily. Based on these results, a low initial dose of rosuvastatin (5 mg) and atorvastatin (10 mg) is recommended when combined with TPV/r, with careful clinical monitoring of rosuvastatin- or atorvastatin-related AEs, such as myopathy.</p></div><div id="__ackid723511" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ackid723511title" style="text-transform: uppercase;">Acknowledgments</h2><div class="sec"><p id="__p40">The study participants and the study nurses are kindly acknowledged for their invaluable help with this study. Jan M. Wruck (Boehringer Ingelheim US) and Peter Jones (Boehringer Ingelheim UK) are gratefully acknowledged for the statistical analyses of these clinical studies.</p><p id="__p41">D.W.C. is supported by a Career Scientist Award from the Ontario HIV Treatment Network of the Ontario Ministry of Health. D.W.C. and C.J.L.L. have received grants and contracts for this and other research from Boehringer Ingelheim US through their institution and employer, the University of Ottawa at The Ottawa Hospital and the Ottawa Health Research Institute. The rosuvastatin study is supported by a GCRC grant (RR-00052) and an investigator-initiated grant from Boehringer Ingelheim Pharmaceuticals, Inc.</p></div></div><div id="__fn-groupid734049" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__fn-groupid734049title" style="text-transform: uppercase;">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn2"><sup></sup>Published ahead of print on 10 August 2009.</p></div></div><div id="__ref-listid1051862" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid1051862title" style="text-transform: uppercase;">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="r1">1. <span class="citation">American Heart Association. 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. <span class="ref-journal">Circulation</span> <span class="ref-vol">106</span><strong>:</strong>3143-3421.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12485966" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r2">2. <span class="citation">Busti, A. J., A. M. Bain, R. G. Hall II, R. G. Bedimo, R. D. Leff, C. Meek, and R. Mehvar. 2008. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. <span class="ref-journal">J. Cardiovasc. Pharmacol.</span> <span class="ref-vol">51</span><strong>:</strong>605-610.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18520949" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r3">3. <span class="citation">Castro, J. G., and L. Gutierrez. 2002. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. <span class="ref-journal">Am. J. Med.</span> <span class="ref-vol">112</span><strong>:</strong>505.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11959068" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r4">4. <span class="citation">Fetsch, P. A., A. Abati, T. Litman, K. Morisaki, Y. Honjo, K. Mittal, and S. E. Bates. 2006. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. <span class="ref-journal">Cancer Lett.</span> <span class="ref-vol">235</span><strong>:</strong>84-92.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15990223" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r5">5. <span class="citation">Fichtenbaum, C. J., J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, and F. Aweeka. 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. <span class="ref-journal">AIDS</span> <span class="ref-vol">16</span><strong>:</strong>569-577.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11873000" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r6">6. <span class="citation">Gutmann, H., P. Hruz, C. Zimmermann, C. Beglinger, and J. Drewe. 2005. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. <span class="ref-journal">Biochem. Pharmacol.</span> <span class="ref-vol">70</span><strong>:</strong>695-699.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15998509" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r7">7. <span class="citation">Hagenbuch, B., and P. J. Meier. 2003. The superfamily of organic anion transporting polypeptides. <span class="ref-journal">Biochim. Biophys. Acta</span> <span class="ref-vol">1609</span><strong>:</strong>1-18.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12507753" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r8">8. <span class="citation">Hermann, M., A. Asberg, H. Christensen, H. Holdaas, A. Hartmann, and J. L. Reubsaet. 2004. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. <span class="ref-journal">Clin. Pharmacol. Ther.</span> <span class="ref-vol">76</span><strong>:</strong>388-391.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15470339" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r9">9. <span class="citation">Hicks, C. B., P. Cahn, D. A. Cooper, S. L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, and H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. <span class="ref-journal">Lancet</span> <span class="ref-vol">368</span><strong>:</strong>466-475.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16890833" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r10">10. <span class="citation">Hirano, M., K. Maeda, Y. Shitara, and Y. Sugiyama. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. <span class="ref-journal">J. Pharmacol. Exp. Ther.</span> <span class="ref-vol">311</span><strong>:</strong>139-146.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15159445" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r11">11. <span class="citation">Hsyu, P. H., M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis, and B. M. Kerr. 2001. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. <span class="ref-journal">Antimicrob. Agents Chemother.</span> <span class="ref-vol">45</span><strong>:</strong>3445-3450. <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11709322" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r12">12. <span class="citation">Huang, L., Y. Wang, and S. Grimm. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. <span class="ref-journal">Drug Metab. Dispos.</span> <span class="ref-vol">34</span><strong>:</strong>738-742.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16415124" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r13">13. <span class="citation">Keskitalo, J. E., O. Zolk, M. F. Fromm, K. J. Kurkinen, P. J. Neuvonen, and M. Niemi. 2009. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. <span class="ref-journal">Clin. Pharmacol. Ther.</span> <span class="ref-vol">86</span><strong>:</strong>197-203.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r14">14. <span class="citation">Kiser, J. J., J. G. Gerber, J. A. Predhomme, P. Wolfe, D. M. Flynn, and D. W. Hoody. 2008. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. <span class="ref-journal">J. Acquir. Immune Defic. Syndr.</span> <span class="ref-vol">47</span><strong>:</strong>570-578.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18176327" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r15">15. <span class="citation">Lennerns, H. 2003. Clinical pharmacokinetics of atorvastatin. <span class="ref-journal">Clin. Pharmacokinet.</span> <span class="ref-vol">42</span><strong>:</strong>1141-1160.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14531725" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r16">16. <span class="citation">MacGregor, T. R., J. P. Sabo, S. H. Norris, P. Johnson, L. Galitz, and S. McCallister. 2004. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. <span class="ref-journal">HIV Clin. Trials</span> <span class="ref-vol">5</span><strong>:</strong>371-382.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15682350" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r17">17. <span class="citation">Maliepaard, M., G. L. Scheffer, I. F. Faneyte, M. A. van Gastelen, A. C. Pijnenborg, A. H. Schinkel, M. J. van De Vijver, R. J. Scheper, and J. H. Schellens. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. <span class="ref-journal">Cancer Res.</span> <span class="ref-vol">61</span><strong>:</strong>3458-3464.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11309308" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r18">18. <span class="citation">Maltz, H. C., D. L. Balog, and J. S. Cheigh. 1999. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. <span class="ref-journal">Ann. Pharmacother.</span> <span class="ref-vol">33</span><strong>:</strong>1176-1179.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10573315" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r19">19. <span class="citation">Matsson, P., G. Englund, G. Ahlin, C. A. Bergstrom, U. Norinder, and P. Artursson. 2007. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). <span class="ref-journal">J. Pharmacol. Exp. Ther.</span> <span class="ref-vol">323</span><strong>:</strong>19-30.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17616561" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r20">20. <span class="citation">Merino, G., J. W. Jonker, E. Wagenaar, A. E. van Herwaarden, and A. H. Schinkel. 2005. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. <span class="ref-journal">Mol. Pharmacol.</span> <span class="ref-vol">67</span><strong>:</strong>1758-1764.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15709111" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r21">21. <span class="citation">Omar, M. A., and J. P. Wilson. 2002. FDA adverse event reports on statin-associated rhabdomyolysis. <span class="ref-journal">Ann. Pharmacother.</span> <span class="ref-vol">36</span><strong>:</strong>288-295.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11847951" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r22">22. <span class="citation">Penzak, S. R., J. M. Shen, R. M. Alfaro, A. T. Remaley, V. Natarajan, and J. Falloon. 2004. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. <span class="ref-journal">Ther. Drug Monit.</span> <span class="ref-vol">26</span><strong>:</strong>322-330.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15167636" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r23">23. <span class="citation">Posvar, E. L., L. L. Radulovic, D. D. Cilla, Jr., L. R. Whitfield, and A. J. Sedman. 1996. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. <span class="ref-journal">J. Clin. Pharmacol.</span> <span class="ref-vol">36</span><strong>:</strong>728-731.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8877677" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r24">24. <span class="citation">Simonson, S. G., A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass, and D. W. Schneck. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. <span class="ref-journal">Clin. Pharmacol. Ther.</span> <span class="ref-vol">76</span><strong>:</strong>167-177.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r25">25. <span class="citation">Tirona, R. G., B. F. Leake, A. W. Wolkoff, and R. B. Kim. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. <span class="ref-journal">J. Pharmacol. Exp. Ther.</span> <span class="ref-vol">304</span><strong>:</strong>223-228.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12490595" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r26">26. <span class="citation">van Heeswijk, R. P., A. Veldkamp, J. W. Mulder, P. L. Meenhorst, J. M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2001. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. <span class="ref-journal">Antivir. Ther.</span> <span class="ref-vol">6</span><strong>:</strong>201-229.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11878403" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r27">27. <span class="citation">Weiss, J., J. Rose, C. H. Storch, N. Ketabi-Kiyanvash, A. Sauer, W. E. Haefeli, and T. Efferth. 2007. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. <span class="ref-journal">J. Antimicrob. Chemother.</span> <span class="ref-vol">59</span><strong>:</strong>238-245.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17202245" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="r28">28. <span class="citation">Ye, Z. W., P. Augustijns, and P. Annaert. 2008. Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. <span class="ref-journal">Drug Metab. Dispos.</span> <span class="ref-vol">36</span><strong>:</strong>1315-1321.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18420783" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#__abstractid1035137title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#__sec1title">MATERIALS AND METHODS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#__sec12title">RESULTS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#__sec19title">DISCUSSION</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#__ackid723511title">Acknowledgments</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#__fn-groupid734049title">Footnotes</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#__ref-listid1051862title">REFERENCES</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">Antimicrobial Agents and Chemotherapy</span> are provided here courtesy of <strong>American Society for Microbiology (ASM)</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/?report=reader"><img src="./PMC2764168_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/pdf/0449-09.pdf">PDF (203K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" data-citationid="PMC2764168" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2764168%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2764168_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2764168%2F&amp;text=Differential%20Effects%20of%20Tipranavir%20plus%20Ritonavir%20on%20Atorvastatin%20or%20Rosuvastatin%20Pharmacokinetics%20in%20Healthy%20Volunteers%20" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2764168_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2764168%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2764168_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="19667285" data-aiid="2764168" data-aid="2764168" data-iid="182333" data-domainid="82" data-domain="aac" data-accid="PMC2764168" data-md5="f6d1b8509c6f79c8eec180783ebd484c">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-37" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-37" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="2764168"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-39" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-39" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/18176327" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.</a><span class="source">[J Acquir Immune Defic Syndr. 2...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):570-8. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/19721063" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.</a><span class="source">[Antimicrob Agents Chemother. 2...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">la Porte CJ, Sabo JP, Bque L, Cameron DW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antimicrob Agents Chemother. 2009 Nov; 53(11):4840-4. Epub 2009 Aug 31.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21712498" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.</a><span class="source">[J Clin Pharmacol. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Pharmacol. 2012 Jun; 52(6):922-31. Epub 2011 Jun 28.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/16802849" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Tipranavir: a novel nonpeptidic protease inhibitor of HIV.</a><span class="source">[Clin Pharmacokinet. 2006]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">King JR, Acosta EP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacokinet. 2006; 45(7):665-82. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22839720" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">[Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].</a><span class="source">[Kardiologiia. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-49" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gogolashvili NG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Kardiologiia. 2012; 52(7):84-92. </em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=19667285&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=19667285&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-51" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-51" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287283/" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transportan Update</a><span class="source">[The AAPS Journal. 2014]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mao Q, Unadkat JD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">The AAPS Journal. 2014 Sep 19; 17(1)65-82</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750718/" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Influence of Drug Transport Proteins on Pharmacokinetics and Drug Interactions of HIV Protease Inhibitors</a><span class="source">[Journal of pharmaceutical scie...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-55" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Griffin L, Annaert P, Brouwer K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of pharmaceutical sciences. 2011 Jun 22; 100(9)3636-3654</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691435/" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">DrugDrug Interaction Studies: Regulatory Guidance and An Industry Perspective</a><span class="source">[The AAPS Journal. 2013]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-57" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Prueksaritanont T, Chu X, Gibson C, Cui D, Yee KL, Ballard J, Cabalu T, Hochman J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">The AAPS Journal. 2013 Mar 30; 15(3)629-645</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264873/" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical DrugDrug Interactions</a><span class="source">[Pharmaceutical Research. 2011]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-59" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Karlgren M, Ahlin G, Bergstrm CA, Svensson R, Palm J, Artursson P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmaceutical Research. 2011 Aug 23; 29(2)411-426</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin</a><span class="source">[Antimicrobial Agents and Chemo...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-61" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antimicrobial Agents and Chemotherapy. 2011 Oct; 55(10)4569-4574</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/citedby/" ref="reftype=relart&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-63" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-63" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=2764168" ref="reftype=Compound&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-65" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=2764168" ref="reftype=MedGen&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-67" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/19667285/" ref="reftype=PubMed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-69" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=2764168" ref="reftype=Substance&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-71" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-73" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-73" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2abd7fd84438f0ea7c98">Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastati...</a><div class="ralinkpop offscreen_noflow">Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers <div class="brieflinkpopdesc">Antimicrobial Agents and Chemotherapy. 2009 Oct; 53(10)4385</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2abb7fd84438f0ea7c2f">PMC2764168 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2aa3f2911de5257e0aa0">Decrease in the oral bioavailability of dabigatran etexilate after co-medication...</a><div class="ralinkpop offscreen_noflow">Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2012 Sep; 74(3)490</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2aa1f0c03b798175fa02">PMC3477350 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2a8cf2911de5257e06be">Case report of exercise and statin-fibrate combination therapy-caused myopathy i...</a><div class="ralinkpop offscreen_noflow">Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways<div class="brieflinkpopdesc">BMC Research Notes. 2013; 6()52</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p4" name="crb--__p4" rid="__p4" style="position: absolute; visibility: visible; width: 370px; top: 791px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-75"><ul>
<li class="two_line" reference_id="r9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16890833/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.</a><span class="one_line_source">[Lancet.  2006]</span><div class="alt-note">
<div class="authors">Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H, RESIST investigator group</div>
<div class="citation">Lancet. 2006 Aug 5; 368(9534):466-75.</div>
</div>
</li>
<li class="two_line" reference_id="r1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12485966/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.</a><span class="one_line_source">[Circulation.  2002]</span><div class="alt-note">
<div class="authors">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</div>
<div class="citation">Circulation. 2002 Dec 17; 106(25):3143-421.</div>
</div>
</li>
<li class="two_line" reference_id="r5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11873000/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.</a><span class="one_line_source">[AIDS.  2002]</span><div class="alt-note">
<div class="authors">Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, NIAID AIDS Clinical Trials Group</div>
<div class="citation">AIDS. 2002 Mar 8; 16(4):569-77.</div>
</div>
</li>
<li class="two_line" reference_id="r15">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14531725/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Clinical pharmacokinetics of atorvastatin.</a><span class="one_line_source">[Clin Pharmacokinet.  2003]</span><div class="alt-note">
<div class="authors">Lennerns H</div>
<div class="citation">Clin Pharmacokinet. 2003; 42(13):1141-60.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p17" name="crb--__p17" rid="__p17" style="position: absolute; visibility: visible; width: 370px; top: 3190px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-76"><ul><li class="two_line" reference_id="r16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15682350/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.</a><span class="one_line_source">[HIV Clin Trials.  2004]</span><div class="alt-note">
<div class="authors">MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S</div>
<div class="citation">HIV Clin Trials. 2004 Nov-Dec; 5(6):371-82.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p27" name="crb--__p27" rid="__p27" style="position: absolute; visibility: visible; width: 370px; top: 4983px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-77"><ul><li class="two_line" reference_id="r9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16890833/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.</a><span class="one_line_source">[Lancet.  2006]</span><div class="alt-note">
<div class="authors">Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H, RESIST investigator group</div>
<div class="citation">Lancet. 2006 Aug 5; 368(9534):466-75.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p35" name="crb--__p35" rid="__p35" style="position: absolute; visibility: visible; width: 370px; top: 6832px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-78"><ul>
<li class="two_line" reference_id="r12">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16415124/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.</a><span class="one_line_source">[Drug Metab Dispos.  2006]</span><div class="alt-note">
<div class="authors">Huang L, Wang Y, Grimm S</div>
<div class="citation">Drug Metab Dispos. 2006 May; 34(5):738-42.</div>
</div>
</li>
<li class="two_line" reference_id="r7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12507753/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> The superfamily of organic anion transporting polypeptides.</a><span class="one_line_source">[Biochim Biophys Acta.  2003]</span><div class="alt-note">
<div class="authors">Hagenbuch B, Meier PJ</div>
<div class="citation">Biochim Biophys Acta. 2003 Jan 10; 1609(1):1-18.</div>
</div>
</li>
<li class="two_line" reference_id="r10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15159445/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.</a><span class="one_line_source">[J Pharmacol Exp Ther.  2004]</span><div class="alt-note">
<div class="authors">Hirano M, Maeda K, Shitara Y, Sugiyama Y</div>
<div class="citation">J Pharmacol Exp Ther. 2004 Oct; 311(1):139-46.</div>
</div>
</li>
<li class="two_line" reference_id="r4">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15990223/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.</a><span class="one_line_source">[Cancer Lett.  2006]</span><div class="alt-note">
<div class="authors">Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE</div>
<div class="citation">Cancer Lett. 2006 Apr 8; 235(1):84-92.</div>
</div>
</li>
<li class="two_line" reference_id="r17">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11309308/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.</a><span class="one_line_source">[Cancer Res.  2001]</span><div class="alt-note">
<div class="authors">Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH</div>
<div class="citation">Cancer Res. 2001 Apr 15; 61(8):3458-64.</div>
</div>
</li>
<li class="two_line" reference_id="r6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15998509/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract.</a><span class="one_line_source">[Biochem Pharmacol.  2005]</span><div class="alt-note">
<div class="authors">Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J</div>
<div class="citation">Biochem Pharmacol. 2005 Sep 1; 70(5):695-9.</div>
</div>
</li>
<li class="two_line" reference_id="r20">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15709111/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.</a><span class="one_line_source">[Mol Pharmacol.  2005]</span><div class="alt-note">
<div class="authors">Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH</div>
<div class="citation">Mol Pharmacol. 2005 May; 67(5):1758-64.</div>
</div>
</li>
<li class="two_line" reference_id="r13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2009]</span><div class="alt-note">
<div class="authors">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M</div>
<div class="citation">Clin Pharmacol Ther. 2009 Aug; 86(2):197-203.</div>
</div>
</li>
<li class="two_line" reference_id="r8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15470339/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.</a><span class="one_line_source">[Clin Pharmacol Ther.  2004]</span><div class="alt-note">
<div class="authors">Hermann M, Asberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JL</div>
<div class="citation">Clin Pharmacol Ther. 2004 Oct; 76(4):388-91.</div>
</div>
</li>
<li class="two_line" reference_id="r24">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.</a><span class="one_line_source">[Clin Pharmacol Ther.  2004]</span><div class="alt-note">
<div class="authors">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW</div>
<div class="citation">Clin Pharmacol Ther. 2004 Aug; 76(2):167-77.</div>
</div>
</li>
<li class="two_line" reference_id="r19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17616561/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).</a><span class="one_line_source">[J Pharmacol Exp Ther.  2007]</span><div class="alt-note">
<div class="authors">Matsson P, Englund G, Ahlin G, Bergstrm CA, Norinder U, Artursson P</div>
<div class="citation">J Pharmacol Exp Ther. 2007 Oct; 323(1):19-30.</div>
</div>
</li>
<li class="two_line" reference_id="r27" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17202245/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.</a><span class="one_line_source">[J Antimicrob Chemother.  2007]</span><div class="alt-note">
<div class="authors">Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T</div>
<div class="citation">J Antimicrob Chemother. 2007 Feb; 59(2):238-45.</div>
</div>
</li>
<li class="two_line" reference_id="r25" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12490595/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.</a><span class="one_line_source">[J Pharmacol Exp Ther.  2003]</span><div class="alt-note">
<div class="authors">Tirona RG, Leake BF, Wolkoff AW, Kim RB</div>
<div class="citation">J Pharmacol Exp Ther. 2003 Jan; 304(1):223-8.</div>
</div>
</li>
<li class="two_line" reference_id="r28" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18420783/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.</a><span class="one_line_source">[Drug Metab Dispos.  2008]</span><div class="alt-note">
<div class="authors">Ye ZW, Augustijns P, Annaert P</div>
<div class="citation">Drug Metab Dispos. 2008 Jul; 36(7):1315-21.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p36" name="crb--__p36" rid="__p36" style="position: absolute; visibility: visible; width: 370px; top: 7328px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-79"><ul>
<li class="two_line" reference_id="r4">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15990223/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.</a><span class="one_line_source">[Cancer Lett.  2006]</span><div class="alt-note">
<div class="authors">Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE</div>
<div class="citation">Cancer Lett. 2006 Apr 8; 235(1):84-92.</div>
</div>
</li>
<li class="two_line" reference_id="r23">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8877677/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.</a><span class="one_line_source">[J Clin Pharmacol.  1996]</span><div class="alt-note">
<div class="authors">Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ</div>
<div class="citation">J Clin Pharmacol. 1996 Aug; 36(8):728-31.</div>
</div>
</li>
<li class="two_line" reference_id="r5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11873000/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.</a><span class="one_line_source">[AIDS.  2002]</span><div class="alt-note">
<div class="authors">Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, NIAID AIDS Clinical Trials Group</div>
<div class="citation">AIDS. 2002 Mar 8; 16(4):569-77.</div>
</div>
</li>
<li class="two_line" reference_id="r22">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15167636/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.</a><span class="one_line_source">[Ther Drug Monit.  2004]</span><div class="alt-note">
<div class="authors">Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J</div>
<div class="citation">Ther Drug Monit. 2004 Jun; 26(3):322-30.</div>
</div>
</li>
<li class="two_line" reference_id="r26">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11878403/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.</a><span class="one_line_source">[Antivir Ther.  2001]</span><div class="alt-note">
<div class="authors">van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM</div>
<div class="citation">Antivir Ther. 2001 Dec; 6(4):201-29.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p37" name="crb--__p37" rid="__p37" style="position: absolute; visibility: visible; width: 370px; top: 7664px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-80"><ul>
<li class="two_line" reference_id="r14">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18176327/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.</a><span class="one_line_source">[J Acquir Immune Defic Syndr.  2008]</span><div class="alt-note">
<div class="authors">Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW</div>
<div class="citation">J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):570-8.</div>
</div>
</li>
<li class="two_line" reference_id="r27">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17202245/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.</a><span class="one_line_source">[J Antimicrob Chemother.  2007]</span><div class="alt-note">
<div class="authors">Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T</div>
<div class="citation">J Antimicrob Chemother. 2007 Feb; 59(2):238-45.</div>
</div>
</li>
<li class="two_line" reference_id="r2">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18520949/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.</a><span class="one_line_source">[J Cardiovasc Pharmacol.  2008]</span><div class="alt-note">
<div class="authors">Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C, Mehvar R</div>
<div class="citation">J Cardiovasc Pharmacol. 2008 Jun; 51(6):605-10.</div>
</div>
</li>
<li class="two_line" reference_id="r5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11873000/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.</a><span class="one_line_source">[AIDS.  2002]</span><div class="alt-note">
<div class="authors">Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, NIAID AIDS Clinical Trials Group</div>
<div class="citation">AIDS. 2002 Mar 8; 16(4):569-77.</div>
</div>
</li>
<li class="two_line" reference_id="r11">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11709322/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.</a><span class="one_line_source">[Antimicrob Agents Chemother.  2001]</span><div class="alt-note">
<div class="authors">Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM</div>
<div class="citation">Antimicrob Agents Chemother. 2001 Dec; 45(12):3445-50.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p38" name="crb--__p38" rid="__p38" style="position: absolute; visibility: visible; width: 370px; top: 8281px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-81"><ul>
<li class="two_line" reference_id="r21">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11847951/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> FDA adverse event reports on statin-associated rhabdomyolysis.</a><span class="one_line_source">[Ann Pharmacother.  2002]</span><div class="alt-note">
<div class="authors">Omar MA, Wilson JP</div>
<div class="citation">Ann Pharmacother. 2002 Feb; 36(2):288-95.</div>
</div>
</li>
<li class="two_line" reference_id="r3">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11959068/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.</a><span class="one_line_source">[Am J Med.  2002]</span><div class="alt-note">
<div class="authors">Castro JG, Gutierrez L</div>
<div class="citation">Am J Med. 2002 Apr 15; 112(6):505.</div>
</div>
</li>
<li class="two_line" reference_id="r18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10573315/" ref="reftype=pubmed&amp;article-id=2764168&amp;issue-id=182333&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.</a><span class="one_line_source">[Ann Pharmacother.  1999]</span><div class="alt-note">
<div class="authors">Maltz HC, Balog DL, Cheigh JS</div>
<div class="citation">Ann Pharmacother. 1999 Nov; 33(11):1176-9.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC2764168_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-r9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.<div class="authors">Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H, RESIST investigator group</div><div class="citation">Lancet. 2006 Aug 5; 368(9534):466-75.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16890833/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r9">Ref list</a>]</p></div><div id="body-link-popper-r1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.<div class="authors">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</div><div class="citation">Circulation. 2002 Dec 17; 106(25):3143-421.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12485966/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r1">Ref list</a>]</p></div><div id="body-link-popper-r5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.<div class="authors">Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, NIAID AIDS Clinical Trials Group</div><div class="citation">AIDS. 2002 Mar 8; 16(4):569-77.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11873000/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r5">Ref list</a>]</p></div><div id="body-link-popper-r15" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Clinical pharmacokinetics of atorvastatin.<div class="authors">Lennerns H</div><div class="citation">Clin Pharmacokinet. 2003; 42(13):1141-60.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14531725/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r15">Ref list</a>]</p></div><div id="body-link-popper-r16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.<div class="authors">MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S</div><div class="citation">HIV Clin Trials. 2004 Nov-Dec; 5(6):371-82.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15682350/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r16">Ref list</a>]</p></div><div id="body-link-popper-r12" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.<div class="authors">Huang L, Wang Y, Grimm S</div><div class="citation">Drug Metab Dispos. 2006 May; 34(5):738-42.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16415124/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r12">Ref list</a>]</p></div><div id="body-link-popper-r7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> The superfamily of organic anion transporting polypeptides.<div class="authors">Hagenbuch B, Meier PJ</div><div class="citation">Biochim Biophys Acta. 2003 Jan 10; 1609(1):1-18.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12507753/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r7">Ref list</a>]</p></div><div id="body-link-popper-r10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.<div class="authors">Hirano M, Maeda K, Shitara Y, Sugiyama Y</div><div class="citation">J Pharmacol Exp Ther. 2004 Oct; 311(1):139-46.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15159445/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r10">Ref list</a>]</p></div><div id="body-link-popper-r4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.<div class="authors">Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE</div><div class="citation">Cancer Lett. 2006 Apr 8; 235(1):84-92.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15990223/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r4">Ref list</a>]</p></div><div id="body-link-popper-r17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.<div class="authors">Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH</div><div class="citation">Cancer Res. 2001 Apr 15; 61(8):3458-64.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11309308/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r17">Ref list</a>]</p></div><div id="body-link-popper-r6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract.<div class="authors">Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J</div><div class="citation">Biochem Pharmacol. 2005 Sep 1; 70(5):695-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15998509/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r6">Ref list</a>]</p></div><div id="body-link-popper-r20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.<div class="authors">Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH</div><div class="citation">Mol Pharmacol. 2005 May; 67(5):1758-64.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15709111/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r20">Ref list</a>]</p></div><div id="body-link-popper-r13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.<div class="authors">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M</div><div class="citation">Clin Pharmacol Ther. 2009 Aug; 86(2):197-203.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r13">Ref list</a>]</p></div><div id="body-link-popper-r8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.<div class="authors">Hermann M, Asberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JL</div><div class="citation">Clin Pharmacol Ther. 2004 Oct; 76(4):388-91.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15470339/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r8">Ref list</a>]</p></div><div id="body-link-popper-r24" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.<div class="authors">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW</div><div class="citation">Clin Pharmacol Ther. 2004 Aug; 76(2):167-77.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r24">Ref list</a>]</p></div><div id="body-link-popper-r19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).<div class="authors">Matsson P, Englund G, Ahlin G, Bergstrm CA, Norinder U, Artursson P</div><div class="citation">J Pharmacol Exp Ther. 2007 Oct; 323(1):19-30.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17616561/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r19">Ref list</a>]</p></div><div id="body-link-popper-r27" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.<div class="authors">Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T</div><div class="citation">J Antimicrob Chemother. 2007 Feb; 59(2):238-45.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17202245/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r27">Ref list</a>]</p></div><div id="body-link-popper-r25" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.<div class="authors">Tirona RG, Leake BF, Wolkoff AW, Kim RB</div><div class="citation">J Pharmacol Exp Ther. 2003 Jan; 304(1):223-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12490595/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r25">Ref list</a>]</p></div><div id="body-link-popper-r28" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.<div class="authors">Ye ZW, Augustijns P, Annaert P</div><div class="citation">Drug Metab Dispos. 2008 Jul; 36(7):1315-21.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18420783/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r28">Ref list</a>]</p></div><div id="body-link-popper-r23" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.<div class="authors">Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ</div><div class="citation">J Clin Pharmacol. 1996 Aug; 36(8):728-31.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8877677/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r23">Ref list</a>]</p></div><div id="body-link-popper-r22" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.<div class="authors">Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J</div><div class="citation">Ther Drug Monit. 2004 Jun; 26(3):322-30.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15167636/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r22">Ref list</a>]</p></div><div id="body-link-popper-r26" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.<div class="authors">van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM</div><div class="citation">Antivir Ther. 2001 Dec; 6(4):201-29.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11878403/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r26">Ref list</a>]</p></div><div id="body-link-popper-r14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.<div class="authors">Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW</div><div class="citation">J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):570-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18176327/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r14">Ref list</a>]</p></div><div id="body-link-popper-r2" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.<div class="authors">Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C, Mehvar R</div><div class="citation">J Cardiovasc Pharmacol. 2008 Jun; 51(6):605-10.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18520949/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r2">Ref list</a>]</p></div><div id="body-link-popper-r11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.<div class="authors">Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM</div><div class="citation">Antimicrob Agents Chemother. 2001 Dec; 45(12):3445-50.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11709322/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r11">Ref list</a>]</p></div><div id="body-link-popper-r21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> FDA adverse event reports on statin-associated rhabdomyolysis.<div class="authors">Omar MA, Wilson JP</div><div class="citation">Ann Pharmacother. 2002 Feb; 36(2):288-95.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11847951/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r21">Ref list</a>]</p></div><div id="body-link-popper-r3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.<div class="authors">Castro JG, Gutierrez L</div><div class="citation">Am J Med. 2002 Apr 15; 112(6):505.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11959068/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r3">Ref list</a>]</p></div><div id="body-link-popper-r18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.<div class="authors">Maltz HC, Balog DL, Cheigh JS</div><div class="citation">Ann Pharmacother. 1999 Nov; 33(11):1176-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10573315/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#r18">Ref list</a>]</p></div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:30:21-04:00&amp;Host=ptpmc101">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC2764168_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC2764168_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC2764168_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=aac&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC2764168/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc101 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC2764168_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>